New Biotech Stocks To Watch – And More!
Companies involved in spectroscopy, bioelectronic medicine and telemedicine make up the three new biotech stocks to watch highlighted in today’s article, which also highlights new…
stocks
23 Stocks And ETFs That Stand To Benefit From A Biden Administration’s Changes (Or A Split Congress’ Lack Of Change)
From the country’s strategy for tackling COVID-19 to U.S.-China tensions to government regulations, some key changes can be expected under the coming Biden administration. At…
A High Risk/High Reward Way To Play The Shift To Biotech Solutions
When it comes to treating diseases, the author of today’s article notes “It seems that there is a shift away from treating symptoms with chemical…
More Outperformance Ahead For These 2 “Class of 2018” Biotech Stocks?
The two biotech stocks highlighted in today’s article both made their public market debuts in 2018 – and both have performed very well for investors…
This Biotech Stock Could Be A Good “Bad News Buy”
When it comes to the biotech stock that’s the focus of today’s article, which plummeted in mid-October when the company abruptly pulled the plug on…
How To Speculate On This Biotech Stock With “A Historically Bullish Signal Flashing”
The biotech stock highlighted in today’s article is already up 173% so far this year, and now the author advises that “a historically bullish signal…
This Biotech Stock Has High Return Potential – And A Potential Bump In The Road
The biotech company highlighted in today’s article, specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer, is one that…
Product Candidates For Wet Underarms And Dry Eyes Have These 2 Stocks Dripping With Upside Potential
Product candidates for the treatment of excessive underarm sweating on one hand, and dry eye disease on the other, could help the two stocks highlighted…
Biotech Penny Stocks To Buy (Or Bypass)
“Call it what you will, but I think traders who’ve dug into the biotech space initially came for the COVID, then figured out there’s far…
This Preclinical Biotech Is Going Clinical This Year – And Goldman Says It’s A Buy
Today’s article highlights a biotech firm that, after being relatively quiet for several years, the market may begin to take notice of as it goes…